Better Safety Info in Pregnancy Starts with Your Referral
Gastroenterologists need more information on the safety of medications when used in pregnancy. MotherToBaby Pregnancy Studies has over 20 years of experience conducting pregnancy exposure cohort studies. With your patient referrals, our research will produce the scientific evidence you and your patients need to weigh the risks and benefits of given treatments for both mom and baby, allowing you to make informed decisions that minimize maternal and fetal/infant risk.
Rigorously Designed Research Studies
We partner with physicians and patients to monitor pregnancy exposure to gastrointestinal medications. Our strong cohort study design allows our team to tease apart risks that may be associated with underlying disease versus those associated with a medication exposure.
Please consider referring your patients if they fall into either of these two groups:
- Patients who have taken any of the following medications during a current pregnancy:
- Certolizumab (Cimzia®)
- Prucalopride (Motegrity®) – study is also recruiting lactating patients
- Tofacitinib (Xeljanz®)
2. Patients who have Crohn’s disease, functional constipation or ulcerative colitis and have not taken the above medications during pregnancy.
MotherToBaby Pregnancy Studies are conducted by the Organization of Teratology Information Specialists (OTIS) and coordinated by the University of California San Diego. MotherToBaby is listed as a resource for information about medications in pregnancy by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).